Wire · opportunities
FDA clears Biolojic Design's Phase I trial of Trop2- and Nectin-4-targeting multibody ADC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
Biolojic Design received FDA clearance for its IND application to start a global Phase I trial of BD200, a multibody antibody drug conjugate targeting Trop2 and Nectin-4 in solid tumors. The study will evaluate safety and efficacy in about 110 patients with tumors expressing these targets.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to watch for new multibody drug formats gaining regulatory approval as they can enable more adaptive tumour targeting. This FDA clearance opens a window for emerging biotech founders to explore multispecific ADCs beyond standard bispecifics.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics